

MICRO-X TO RECEIVE \$1.3M FOR LUNG CT SCANNER RESEARCH

University of Sydney led research to use Micro-X NEX Technology platform

Adelaide, Australia, 16 June 2026: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a global leader in cold cathode X-ray technology for health and security markets, is pleased to announce it has executed a research agreement with the University of Sydney as part of a \$1.9M research partnership for the application of Nano Electronic X-ray Technology in potential future miniaturised lung CT applications. The funding is provided through the Australian Government's Critical Technologies Challenge Program (**CTCP**).

Key points

- **University of Sydney to lead 18-month research program evaluating the feasibility of a miniaturised stationary CT for lung imaging applications**
- **Micro-X to receive \$1.3M for provision of existing Nano Electronic X-ray hardware and technical support for integration into a lung imaging laboratory test bench**
- **Work will utilise technology previously developed through the Micro-X Head CT program and continue work from Stage 1 of the Critical Technologies Challenge Program.**
- **Project to evaluate feasibility of pursuit of development of a commercial product**

Micro-X Chief Operating Officer Anthony Skeats commented:

"As the leading cause of death from cancer in Australia, lung cancer has a significant impact on families and the community. This funding supports evaluation of our existing NEX Technology in a controlled research environment looking at early lung cancer screening. Our contribution to the program will be providing the established X-ray hardware and technical expertise developed through our earlier Head CT work. The objective is to assess feasibility and better understand the performance characteristics of a stationary architecture for potential deployable lung CT applications."


About the Project - Quantum CT for Lung Cancer Diagnosis

The University of Sydney is leading a \$1.9M research partnership under the Australian Government's Critical Technologies Challenge Program, Round 1 Stage 2. As part of this program, Micro-X is one of the core technology partners, and will receive \$1.3M to provide an existing imaging chain, technical support and services.

The objective of the research program is to establish a laboratory-based, proof-of-concept test bench for detecting lung cancer. This test bench will incorporate multiple Micro-X Nano Electronic X-ray (**NEX**) tubes arranged in a stationary configuration, and will be used to evaluate imaging geometry, photon measurement techniques, and system integration concepts. The test bench is intended to test proof of concept for potential future CT applications and will not be a medical device intended for clinical use.

The project will examine the feasibility of a smaller, lighter and cheaper CT imager incorporating Micro-X stationary NEX-based architecture as an alternative to conventional CT systems. If this early feasibility is successful, any progression will require a robust commercial use case supported by further engineering development, regulatory approvals and additional funding.

Micro-X's role is to supply existing NEX hardware, high-voltage generation components and associated technical expertise. In conjunction, the University of Sydney will lead system-level research activities and software development in collaboration with research and clinical partners.



Lung cancer a global public health issue

Lung cancer is a significant public health challenge globally. It is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. Several countries are implementing early screening programs for high-risk populations, including Australia. This project's funding supports the investigation of enabling technologies that may contribute to future deployable imaging solutions addressing this global clinical need.



Figure 1: Comparison of conventional and possible deployable lung CT imaging systems.

This project builds on Stage One work under the Australian Government funded program, which demonstrated the feasibility of stationary NEX CT array architecture for lung CT in a laboratory setting. The program directly supports Australia's National Quantum Strategy by accelerating the translation of world-leading research into practical, industry-ready solutions.

This ASX Announcement is authorised by the Board of Micro-X.


– ENDS –

About Micro-X

Micro-X Limited is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing X-ray markets and a range of new and unique security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio spans four high margin product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. The US Department of Homeland Security has contracted Micro-X to design a next generation airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances is being developed with funding from the Australian Government's Medical Research Future Fund and Industry Growth Program. Micro-X is developing a full body CT under contract by US Government agency ARPA-H.

For more information visit: www.micro-x.com



Contacts

Micro-X Limited	Investor Enquiries
<p>Kingsley Hall, Chief Executive Officer Rebecca Puddy, Head of Corporate Communications Tel: +61 8 7099 3966 Email: media@micro-x.com</p>	<p>Peter Dickman, Chief Financial Officer Tel: +61 8 7099 3966 Email: pdickman@micro-x.com</p>

For personal use only

